03:38 PM EST, 01/13/2025 (MT Newswires) -- Accuray ( ARAY ) said Monday that it received approval from the Chinese National Medical Products Administration for its Radixact SynC and CyberKnife S7 System.

Radixact SynC is a radiation therapy system designed to deliver precise and personalized treatment to patients with cancer and CyberKnife S7 is a robotic radiosurgery device for treating cancerous and benign tumors, the company said.

Shares of the company were up 2.1% in recent trading.

Price: 2.19, Change: +0.04, Percent Change: +2.10